Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study With an Open-Label Extension in Pediatric Participants to Evaluate the Safety, Efficacy, and Pharmacokinetics of Diroximel Fumarate and Dimethyl Fumarate for the Treatment of Relapsing Forms of Multiple Sclerosis

NCT07483632 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT07483632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study With an Open-Label Extension in Pediatric Participants to Evaluate the Safety, Efficacy, and Pharmacokinetics of Diroximel Fumarate and Dimethyl Fumarate for the Treatment of Relapsing Forms of Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 16, 2026
Completion date
June 19, 2035
Enrollment
185 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing forms of multiple sclerosis